JPRN-jRCT2080224146已完成1 期
A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients with Narcolepsy
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 57 人开始时间: 2018年11月16日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 57
研究概览
简要总结
TAK-925 was safe and well tolerated in the multiple intravenous administrations of up to 180 mg for healthy participants, up to 44 mg for patients with NT1, and up to 112 mg for patients with NT2; and also in single oral administration of 112 mg for healthy participants.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Healthy adult participants and Healthy elderly participants:
- •- Participant weighs at least 50 kg (Healthy adults participants) / 40 kg (Healthy elderly participants) and has a body mass index (BMI) from 18.5 to 30 kg/m^2, inclusive at Screening.
- •Narcolepsy patients:
- •- Patient weighs at least 40 kg inclusive at Screening (>=50 kg is required for Cohort B4).
- •- A diagnosis of narcolepsy, as defined by the International Classification of Sleep Disorders, Third Edition (ICSD-3).
- •- At Day -1, Epworth sleepiness scale (ESS) score >=10
排除标准
- •All Participants:
- •- Participants consume excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
- •- Participants have a moderate to severe substance use disorder.
- •- Participants have a risk of suicide according to endorsement of item 4 or 5 with Screening/Baseline visit C-SSRS or has made a suicide attempt in the previous 6 months.
- •- Participants have a lifetime history of major psychiatric disorder, such as bipolar disorder or schizophrenia.
- •- Participants experienced sleep wake cycle disturbance with external factors such as irregular work hours.
研究者
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses with Titration of TAK-935 in Healthy Japanese ParticipantsJapanese healthy adultJPRN-jRCT2080225253Takeda Pharmaceutical Company Limited33
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy ParticipantsHealthy ParticipantsNCT03933488Takeda121
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male ParticipantsHealthy VolunteersNCT04551079Takeda19
撤回
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy ParticipantsHealthy VolunteersNCT04082481Takeda
已完成
1 期
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics StudyHealthy VolunteersSchizophreniaNCT02748694Neurocrine Biosciences114